MARTINSRIED/MUNICH, Germany, & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that enrollment has opened in a Phase 1 study evaluating RGB-286638 in patients with advanced solid tumors. This is the first time that this novel drug candidate is being studied in human clinical trials.
